Bibliografía del artículo
1. Jaumdally R, Varma C, Macfadyen RJ, et al. Coronary sinus blood sampling: an insight into local cardiac pathophysiology and treatment? Eur Heart J 28:929-940, 2007.
2. Winters KJ, Lasala JM, Eisenberg PR, et al. Modified heparin-bonded catheter for cannulation of the coronary sinus from the femoral vein. Cathet Cardiovasc Diagn 39:433-437, 1996.
3. Economopoulos GC, Michalis A, Palatianos GM, et al. Management of catheter-related injuries to the coronary sinus. Ann Thorac Surg 76:112-116, 2003.
4. Nichols AB, Owen J, Grossman BA, et al. Effect of heparin bonding on catheter-induced fibrin formation and platelet activation. Circulation 70:843-850, 1984.
5. Ross R. Atherosclerosis: an inflammatory disease. New Engl J Med 340:115-126, 1999.
6. Saadeddin SM, Habbab MA, Ferns GA. Markers of inflammation and coronary artery disease. Med Sci Monit 8:RA5-12, 2002.
7. Montavi A. The interplay between primary and secondary cytokines: cytokines involved in the regulation of monocyte recruitment. Drugs 97(Suppl.I):15-23, 1997.
8. Lotz M. Interleukin-6. Cancer Invest 11:732-742, 1993.
9. Ganter U, Arcone R, Toniatti C, Morrone G, Ciliberto G. Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J 8:3773-3779, 1989.
10. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem 47:403-411, 2001.
11. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Br Med J 321:199-204, 2000.
12. Ramadan MM, Kodama M, Mitsuma W, et al. Impact of percutaneous coronary intervention on the levels of interleukin-6 and C-reactive protein in the coronary circulation of subjects with coronary artery disease. Am J Cardiol 98:915-917, 2006.
13. Ellis SG, Vandormael MG, Cowley MJ, et al. The Multivessel Angioplasty Prognosis Study Group. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection. Circulation 82:1193-1202, 1990.
14. Versaci F, Gaspardone A, Tomai F. Predictive value of C-reactive protein in patients with unstable angina undergoing coronary stent implantation. Am J Cardiol 58:92-95, 2000.
15. Sukovich DA, Kauser K, Shirley FD, DelVecchio V, Halks-Miller M, Rubanyi GM. Expression of interleukin-6 in atherosclerotic lesions of male ApoE-knockout mice. Arterioscler Thromb Vasc Biol 18:1498-1505, 1998.
16. Cushing SD, Berliner JA, Valente AJ, et al. Minimally modified lowdensity lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 87:5134-5138, 1990.
17. Rus HG, Vlaicu R, Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 127:263-267, 1996.
18. Ishikawa T, Hatakeyama K, Imamura T, et al. Involvement of C-reactive protein obtained by directional coronary atherectomy in plaque instability and developing restenosis in patients with stable or unstable angina pectoris. Am J Cardiol 91:287-292, 2003.
19. De Maat MP, Kluft C. The association between inflammation markers, coronary artery disease and smoking. Vasc Pharmacol 39:137-139, 2002.
20. Baumann H, Morella KK, Wong GH. TNF-alpha, IL-1 beta, and hepatocyte growth factor cooperate in stimulating specific acute phase plasma protein genes in rat hepatoma cells. J Immunol 151:4248-4257, 1993.
21. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 88:1785-1792, 1991.
22. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 272:20963-20966, 1997.
23. Yamashita H, Ehara S, Yoshiyama M, et al. Elevated plasma levels of oxidized low-density lipoprotein relate to the presence of angiographically detected complex and thrombotic coronary artery lesion morphology in patients with unstable angina. Circ J 71:681-687, 2007.
24. Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low-density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103:1955-1960, 2001.
25. Tsimikas S, Lau HK, Han KR, et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein (a) short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation 109:3164-3170, 2004.
26. Ramadan MM, Kodama M, Hirono S, et al. Evaluation of oxidized low-density lipoprotein in the coronary circulation of patients with coronary artery disease, and its association with percutaneous coronary intervention. Int J Cardiol [in press].
27. Kotani K, Maekawa M, Kanno T, Kondo A, Toda N, Manabe M. Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochem Biophys Acta 1215:111-118, 1994.
28. Podrez EA, Schmitt D, Hoff HF, Hazen SL. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest 103:1547-1560, 1999.
29. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 21:1876-1890, 2001.
30. Heeringa P, Huugen D, Tervaert JW. Anti-neutrophil cytoplasmic autoantibodies and leukocyte-endothelial interactions: a sticky connection? Trends Immunol 26:561-564, 2005.
31. Jennette JC, Wilkman AS, Falk RJ. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol 135:921-930, 1989.
32. Ishida-Okawara A, Oharaseki T, Takahashi K, et al. Contribution of myeloperoxidase to coronary artery vasculitis associated with MPOANCA production. Inflammation 25:381-387, 2001.
33. Ramadan MM, Tachikawa H, Kodama M, et al. A pilot-controled study of myeloperoxidase-specific anti-neutrophil cytoplasmic autoantibody (MPO-ANCA) in the coronary circulation. Int J Cardiol [in press].
34. Kritchevsky SB, Cesari M, Pahor M. Inflammatory markers and cardiovascular health in older adults. Cardiovasc Res 66:265-275, 2005.
35. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685-1695, 2005.
36. Jennette JC, Xiao H, Falk RJ. Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol 17:1235-1242, 2006.
37. Falk RJ, Terrel RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic antibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 87:4115-4119, 1990.